Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Evolution of CRISPR-associated endonucleases as inferred from resurrected proteins

Nature Microbiology volume 8, pages 77–90 (2023)Cite this article

Subjects

Abstract

Clustered regularly interspaced short palindromic repeats (CRISPR)-associated Cas9 is an effector protein that targets invading DNA and plays a major role in the prokaryotic adaptive immune system. Although Streptococcus pyogenes CRISPR–Cas9 has been widely studied and repurposed for applications including genome editing, its origin and evolution are poorly understood. Here, we investigate the evolution of Cas9 from resurrected ancient nucleases (anCas) in extinct firmicutes species that last lived 2.6 billion years before the present. We demonstrate that these ancient forms were much more flexible in their guide RNA and protospacer-adjacent motif requirements compared with modern-day Cas9 enzymes. Furthermore, anCas portrays a gradual palaeoenzymatic adaptation from nickase to double-strand break activity, exhibits high levels of activity with both single-stranded DNA and single-stranded RNA targets and is capable of editing activity in human cells. Prediction and characterization of anCas with a resurrected protein approach uncovers an evolutionary trajectory leading to functionally flexible ancient enzymes.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Phylogenetic and structural analysis of anCas endonucleases.
Fig. 2: Activity of anCas endonucleases on a supercoiled DNA substrate.
Fig. 3: PAM determination of anCas.
Fig. 4: HT-PAMDA assay.
Fig. 5: sgRNA test and nuclease activity of anCas on single-stranded substrates.
Fig. 6: Activity of anCas endonucleases in human HEK293T cells.

Similar content being viewed by others

Data availability

We have made available sequencing data. Other data supporting the findings of this study are available from the corresponding authors upon reasonable request. Plasmids for gene editing in human cells are available through Addgene (Supplementary Table 14 and https://www.addgene.org/Raul_Perez-Jimenez/). Plasmids for HT-PAMDA experiments are available through Addgene (Supplementary Tables 8–10 and www.addgene.org/Benjamin_Kleinstiver/). Sequencing data for PAM determination and gene editing experiments will be made available through the National Center for Biotechnology Information Sequence Read Archive (NCBI SRA) under BioProject ID PRJNA832610. Sequencing data for HT-PAMDA experiments will be made available through NCBI SRA under BioProject ID PRJNA832159. Source data are provided with this paper.

Code availability

Python script used for structure analysis can be found at spectrumBar.py and code used for sequence analysis is available via Zenodo at https://zenodo.org/record/3710516#.Y1plwHbMKUl.

References

  1. Mohanraju, P. et al. Alternative functions of CRISPR–Cas systems in the evolutionary arms race. Nat. Rev. Microbiol. 20, 351–364 (2022).

    Article  CAS  Google Scholar 

  2. Makarova, K. S. et al. Evolutionary classification of CRISPR–Cas systems: a burst of class 2 and derived variants. Nat. Rev. Microbiol. 18, 67–83 (2020).

    Article  CAS  Google Scholar 

  3. Garneau, J. E. et al. The CRISPR/Cas bacterial immune system cleaves bacteriophage and plasmid DNA. Nature 468, 67–71 (2010).

    Article  CAS  Google Scholar 

  4. Barrangou, R. et al. CRISPR provides acquired resistance against viruses in prokaryotes. Science 315, 1709–1712 (2007).

    Article  CAS  Google Scholar 

  5. Karginov, F. V. & Hannon, G. J. The CRISPR system: small RNA-guided defense in bacteria and archaea. Mol. Cell 37, 7–19 (2010).

    Article  CAS  Google Scholar 

  6. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in daaptive bacterial immunity. Science 337, 816–821 (2012).

    Article  CAS  Google Scholar 

  7. Mojica, F. J., Diez-Villasenor, C., Garcia-Martinez, J. & Almendros, C. Short motif sequences determine the targets of the prokaryotic CRISPR defence system. Microbiology 155, 733–740 (2009).

    Article  CAS  Google Scholar 

  8. McGinn, J. & Marraffini, L. A. Molecular mechanisms of CRISPR–Cas spacer acquisition. Nat. Rev. Microbiol. 17, 7–12 (2019).

    Article  CAS  Google Scholar 

  9. Anders, C., Niewoehner, O., Duerst, A. & Jinek, M. Structural basis of PAM-dependent target DNA recognition by the Cas9 endonuclease. Nature 513, 569–573 (2014).

    Article  CAS  Google Scholar 

  10. Singh, D., Sternberg, S. H., Fei, J., Doudna, J. A. & Ha, T. Real-time observation of DNA recognition and rejection by the RNA-guided endonuclease Cas9. Nat. Commun. 7, 12778 (2016).

    Article  CAS  Google Scholar 

  11. Mali, P., Esvelt, K. M. & Church, G. M. Cas9 as a versatile tool for engineering biology. Nat. Methods 10, 957–963 (2013).

    Article  CAS  Google Scholar 

  12. Sternberg, S. H., Redding, S., Jinek, M., Greene, E. C. & Doudna, J. A. DNA interrogation by the CRISPR RNA-guided endonuclease Cas9. Nature 507, 62–67 (2014).

    Article  CAS  Google Scholar 

  13. Koonin, E. V. & Makarova, K. S. Origins and evolution of CRISPR-Cas systems. Philos. Trans. R. Soc. Lond. B Biol. Sci. 374, 20180087 (2019).

    Article  CAS  Google Scholar 

  14. Manteca, A. et al. Mechanochemical evolution of the giant muscle protein titin as inferred from resurrected proteins. Nat. Struct. Mol. Biol. 24, 652–657 (2017).

    Article  CAS  Google Scholar 

  15. Perez-Jimenez, R. et al. Single-molecule paleoenzymology probes the chemistry of resurrected enzymes. Nat. Struct. Mol. Biol. 18, 592–596 (2011).

    Article  CAS  Google Scholar 

  16. Barruetabeña, N. et al. Resurrection of efficient Precambrian endoglucanases for lignocellulosic biomass hydrolysis. Commun. Chem. 2, 76 (2019).

    Article  Google Scholar 

  17. Zakas, P. M. et al. Enhancing the pharmaceutical properties of protein drugs by ancestral sequence reconstruction. Nat. Biotechnol. 35, 35–37 (2017).

    Article  CAS  Google Scholar 

  18. Nishimasu, H. et al. Crystal structure of Cas9 in complex with guide RNA and target DNA. Cell 156, 935–949 (2014).

    Article  CAS  Google Scholar 

  19. Jinek, M. et al. Structures of Cas9 endonucleases reveal RNA-mediated conformational activation. Science 343, 1247997 (2014).

    Article  Google Scholar 

  20. Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature 596, 583–589 (2021).

    Article  CAS  Google Scholar 

  21. Tunyasuvunakool, K. et al. Highly accurate protein structure prediction for the human proteome. Nature 596, 590–596 (2021).

    Article  CAS  Google Scholar 

  22. Varadi, M. et al. AlphaFold Protein Structure Database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 50, D439–D444 (2021).

    Article  Google Scholar 

  23. Karvelis, T. et al. Rapid characterization of CRISPR-Cas9 protospacer adjacent motif sequence elements. Genome Biol. 16, 253 (2015).

    Article  Google Scholar 

  24. Chatterjee, P., Jakimo, N. & Jacobson, J. M. Minimal PAM specificity of a highly similar SpCas9 ortholog. Sci. Adv. 4, eaau0766 (2018).

    Article  CAS  Google Scholar 

  25. Kleinstiver, B. P. et al. Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition. Nat. Biotechnol. 33, 1293–1298 (2015).

    Article  CAS  Google Scholar 

  26. Chatterjee, P. et al. An engineered ScCas9 with broad PAM range and high specificity and activity. Nat. Biotechnol. 38, 1154–1158 (2020).

    Article  CAS  Google Scholar 

  27. Miller, S. M. et al. Continuous evolution of SpCas9 variants compatible with non-G PAMs. Nat. Biotechnol. 38, 471–481 (2020).

    Article  CAS  Google Scholar 

  28. Walton, R. T., Christie, K. A., Whittaker, M. N. & Kleinstiver, B. P. Unconstrained genome targeting with near-PAMless engineered CRISPR-Cas9 variants. Science 368, 290–296 (2020).

    Article  CAS  Google Scholar 

  29. Walton, R. T., Hsu, J. Y., Joung, J. K. & Kleinstiver, B. P. Scalable characterization of the PAM requirements of CRISPR–Cas enzymes using HT-PAMDA. Nat. Protoc. 16, 1511–1547 (2021).

    Article  CAS  Google Scholar 

  30. Gasiunas, G. et al. A catalogue of biochemically diverse CRISPR-Cas9 orthologs. Nat. Commun. 11, 5512 (2020).

    Article  CAS  Google Scholar 

  31. Ma, E., Harrington, L. B., O’Connell, M. R., Zhou, K. & Doudna, J. A. Single-stranded DNA cleavage by divergent CRISPR-cas9 enzymes. Mol. Cell 60, 398–407 (2015).

    Article  CAS  Google Scholar 

  32. Feng, W. et al. CRISPR technology incorporating amplification strategies: molecular assays for nucleic acids, proteins, and small molecules. Chem. Sci. 12, 4683–4698 (2021).

    Article  CAS  Google Scholar 

  33. Chen, J. S. et al. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. Science 360, 436–439 (2018).

    Article  CAS  Google Scholar 

  34. Charlesworth, C. T. et al. Identification of preexisting adaptive immunity to Cas9 proteins in humans. Nat. Med. 25, 249–254 (2019).

    Article  CAS  Google Scholar 

  35. Fernández, A. et al. Genetics of non-syndromic and syndromic oculocutaneous albinism in human and mouse. Pigment Cell Melanoma Res. 34, 786–799 (2021).

    Article  Google Scholar 

  36. Cervera, S. T. et al. Therapeutic potential of EWSR1–FLI1 inactivation by CRISPR/Cas9 in Ewing sarcoma. Cancers 13, 3783 (2021).

    Article  CAS  Google Scholar 

  37. Wang, J.A.-O., Pausch, P.A.-O. & Doudna, J.A.-O.X. Structural biology of CRISPR-Cas immunity and genome editing enzymes. Nat. Rev. Microbiol. https://doi.org/10.1038/s41579-022-00739-4 (2022).

  38. Risso, V. A., Gavira, J. A., Mejia-Carmona, D. F., Gaucher, E. A. & Sanchez-Ruiz, J. M. Hyperstability and substrate promiscuity in laboratory resurrections of Precambrian beta-lactamases. JACS Au. 135, 2899–2902 (2013).

    Article  CAS  Google Scholar 

  39. Risso, V. A., Gavira, J. A. & Sanchez-Ruiz, J. M. Thermostable and promiscuous Precambrian proteins. Environ. Microbiol. 16, 1485–1489 (2014).

    Article  CAS  Google Scholar 

  40. Merkl, R. & Sterner, R. Ancestral protein reconstruction: techniques and applications. Biol. Chem. 397, 1–21 (2016).

    Article  CAS  Google Scholar 

  41. Jones, B. J. et al. Larger active site in an ancestral hydroxynitrile lyase increases catalytically promiscuous esterase activity. PLoS ONE 15, e0235341 (2020).

    Article  CAS  Google Scholar 

  42. Boussau, B., Blanquart, S., Necsulea, A., Lartillot, N. & Gouy, M. Parallel adaptations to high temperatures in the Archaean eon. Nature 456, 942–945 (2008).

    Article  CAS  Google Scholar 

  43. Blanquart, S. et al. Resurrection of ancestral malate dehydrogenases reveals the evolutionary history of halobacterial proteins: deciphering gene trajectories and changes in biochemical properties. Mol. Biol. Evol. 38, 3754–3774 (2021).

    Article  CAS  Google Scholar 

  44. Risso, V. A. et al. De novo active sites for resurrected Precambrian enzymes. Nat. Commun. 8, 16113 (2017).

    Article  CAS  Google Scholar 

  45. Santiago-Ortiz, J. et al. AAV ancestral reconstruction library enables selection of broadly infectious viral variants. Gene Ther. 22, 934–946 (2015).

    Article  CAS  Google Scholar 

  46. Gumulya, Y. & Gillam, E. M. Exploring the past and the future of protein evolution with ancestral sequence reconstruction: the ‘retro’ approach to protein engineering. Biochem. J. 474, 1–19 (2017).

    Article  CAS  Google Scholar 

  47. Harms, M. J. & Thornton, J. W. Analyzing protein structure and function using ancestral gene reconstruction. Curr. Opin. Struct. Biol. 20, 360–366 (2010).

    Article  CAS  Google Scholar 

  48. Lee, J. K. et al. Directed evolution of CRISPR-Cas9 to increase its specificity. Nat. Commun. 9, 3048 (2018).

    Article  Google Scholar 

  49. Slaymaker, I. M. et al. Rationally engineered Cas9 nucleases with improved specificity. Science 351, 84–88 (2016).

    Article  CAS  Google Scholar 

  50. Kleinstiver, B. P. et al. High-fidelity CRISPR–Cas9 nucleases with no detectable genome-wide off-target effects. Nature 529, 490–495 (2016).

    Article  CAS  Google Scholar 

  51. Burstein, D. et al. New CRISPR–Cas systems from uncultivated microbes. Nature 542, 237–241 (2017).

    Article  CAS  Google Scholar 

  52. Le, S. Q. & Gascuel, O. An improved general amino acid replacement matrix. Mol. Biol. Evol. 25, 1307–1320 (2008).

    Article  CAS  Google Scholar 

  53. Sheridan, P. P., Freeman, K. H. & Brenchley, J. E. Estimated minimal divergence times of the major bacterial and archaeal phyla. Geomicrobiol. J. 20, 1–14 (2003).

    Article  CAS  Google Scholar 

  54. Marin, J., Battistuzzi, F. U., Brown, A. C. & Hedges, S. B. The timetree of prokaryotes: new insights into their evolution and speciation. Mol. Biol. Evol. 34, 437–446 (2016).

    Google Scholar 

  55. Tamura, K. et al. Estimating divergence times in large molecular phylogenies. Proc. Natl Acad. Sci. USA 109, 19333–19338 (2012).

    Article  CAS  Google Scholar 

  56. Kumar, S., Stecher, G., Suleski, M. & Hedges, S. B. TimeTree: a resource for timelines, timetrees, and divergence times. Mol. Biol. Evol. 34, 1812–1819 (2017).

    Article  CAS  Google Scholar 

  57. Hedges, S. B. & Kumar, S. The Timetree of Life (Oxford Univ. Press, 2009).

  58. Krissinel, E. & Henrick, K. Secondary-structure matching (SSM), a new tool for fast protein structure alignment in three dimensions. Acta Crystallogr. D Biol. Crystallogr. 60, 2256–2268 (2004).

    Article  CAS  Google Scholar 

  59. Collaborative Computational Project, No. 4 The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760–763 (1994).

    Article  Google Scholar 

  60. Leenay, R. T. et al. Identifying and visualizing functional PAM diversity across CRISPR-Cas systems. Mol. Cell 62, 137–147 (2016).

    Article  CAS  Google Scholar 

  61. Wang, D. et al. Adenovirus-mediated somatic genome editing of Pten by CRISPR/Cas9 in mouse liver in spite of Cas9-specific immune responses. Hum. Gene Ther. 26, 432–442 (2015).

    Article  CAS  Google Scholar 

  62. Harms, D. W. et al. Mouse genome editing using the CRISPR/Cas system. Curr. Protoc. Hum. Genet https://doi.org/10.1002/0471142905.hg1507s83 (2014).

  63. Oliveros, J. C. et al. Breaking-Cas-interactive design of guide RNAs for CRISPR-Cas experiments for ENSEMBL genomes. Nucleic Acids Res. 44, W267–W271 (2016).

    Article  CAS  Google Scholar 

  64. Seruggia, D., Fernández, A., Cantero, M., Pelczar, P. & Montoliu, L. Functional validation of mouse tyrosinase non-coding regulatory DNA elements by CRISPR–Cas9-mediated mutagenesis. Nucleic Acids Res. 43, 4855–4867 (2015).

    Article  CAS  Google Scholar 

  65. Fernandez, A. et al. Simple protocol for generating and genotyping genome-edited mice with CRISPR-Cas9 reagents. Curr. Protoc. Mouse Biol. 10, e69 (2020).

    Article  CAS  Google Scholar 

  66. López-Márquez, A. A.-O. et al. CRISPR/Cas9-mediated allele-specific disruption of a dominant COL6A1 pathogenic variant improves collagen VI network in patient fibroblasts. Int. J. Mol. Sci. 23, 4410 (2022).

    Article  Google Scholar 

  67. Lindsay, H. et al. CrispRVariants charts the mutation spectrum of genome engineering experiments. Nat. Biotechnol. 34, 701–702 (2016).

    Article  CAS  Google Scholar 

  68. Certo, M. T. et al. Tracking genome engineering outcome at individual DNA breakpoints. Nat. Methods 8, 671–676 (2011).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work has been supported by grant nos. PID2019-109087RB-I00 (to R.P.-J.) and RTI2018-101223-B-I00 and PID2021-127644OB-I00 (to L.M.) from the Spanish Ministry of Science and Innovation. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement no. 964764 (to R.P.-J.). The content presented in this document represents the views of the authors, and the European Commission has no liability in respect to the content. We acknowledge financial support from the Spanish Foundation for the Promotion of Research of Amyotrophic Lateral Sclerosis. A.F. acknowledges Spanish Center for Biomedical Network Research on Rare Diseases (CIBERE) intramural funds (no. ER19P5AC756/2021). F.J.M.M. acknowledges research support by Conselleria d’Educació, Investigació, Cultura i Esport from Generalitat Valenciana, research project nos. PROMETEO/2017/129 and PROMETEO/2021/057. M.M. acknowledges funding from CIBERER (grant no. ER19P5AC728/2021). The work has received funding from the Regional Government of Madrid (grant no. B2017/BMD3721 to M.A.M.-P.) and from Instituto de Salud Carlos III, cofounded with the European Regional Development Fund ‘A way to make Europe’ within the National Plans for Scientific and Technical Research and Innovation 2017–2020 and 2021–2024 (nos. PI17/1659, PI20/0429 and IMP/00009; to M.A.M.-P. B.P.K. was supported by an MGH ECOR Howard M. Goodman Award and NIH P01 HL142494. We thank H. Stutzman for assistance with cloning plasmids, and Z. Herbert and M. Berkeley from the Molecular Biology Core Facilities at the Dana-Farber Cancer Institute for assistance with NextSeq sequencing.

Author information

Author notes

  1. These authors contributed equally: Borja Alonso-Lerma, Ylenia Jabalera.

Authors and Affiliations

  1. CIC nanoGUNE BRTA, San Sebastian, Spain

    Borja Alonso-Lerma, Ylenia Jabalera, Sara Samperio, Ane Quesada-Ganuza, Antonio Reifs & Raul Perez-Jimenez

  2. Servicio de Genética, Hospital Universitario Ramón y Cajal, IRYCIS and Centro de Investigaciones Biomédicas en Red de Enfermedades Raras, Madrid, Spain

    Matias Morin, Sergio Fernández-Peñalver, Lucia Soletto & Miguel A. Moreno-Pelayo

  3. Department of Molecular and Cellular Biology, National Centre for Biotechnology and Centre for Biomedical Network Research on Rare Diseases, Madrid, Spain

    Almudena Fernandez, Yolanda Benitez & Lluis Montoliu

  4. Center for Genomic Medicine and Department of Pathology, Massachusetts General Hospital, Boston, MA, USA

    Logan T. Hille, Rachel A. Silverstein & Benjamin P. Kleinstiver

  5. PhD Program in Biological and Biomedical Sciences, Harvard University, Boston, MA, USA

    Logan T. Hille & Rachel A. Silverstein

  6. INGEMM, Hospital Universitario La Paz, Madrid, Spain

    Yolanda Benitez

  7. Laboratorio de Estudios Cristalográficos, IACT, Armilla, Spain

    Jose A. Gavira

  8. Interuniversity Institute of Bioinformatics in Brussels, ULB-VUB, Brussels, Belgium

    Adrian Diaz & Wim Vranken

  9. Structural Biology Brussels, Vrije Universiteit Brussel, Brussels, Belgium

    Adrian Diaz & Wim Vranken

  10. Structural Biology Research Centre, VIB, Brussels, Belgium

    Wim Vranken

  11. Integra Therapeutics S.L., Barcelona, Spain

    Avencia Sanchez-Mejias & Marc Güell

  12. Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain

    Marc Güell

  13. Dpto. Fisiología, Genética y Microbiología and Instituto Multidisciplinar para el Estudio del Medio ‘Ramón Margalef’, Universidad de Alicante, Alicante, Spain

    Francisco J. M. Mojica

  14. Department of Pathology, Harvard Medical School, Boston, MA, USA

    Benjamin P. Kleinstiver

  15. Ikerbasque Foundation for Science, Bilbao, Spain

    Raul Perez-Jimenez

Authors
  1. Borja Alonso-Lerma
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ylenia Jabalera
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sara Samperio
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Matias Morin
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Almudena Fernandez
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Logan T. Hille
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rachel A. Silverstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ane Quesada-Ganuza
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Antonio Reifs
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Sergio Fernández-Peñalver
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Yolanda Benitez
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Lucia Soletto
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Jose A. Gavira
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Adrian Diaz
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Wim Vranken
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Avencia Sanchez-Mejias
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Marc Güell
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Francisco J. M. Mojica
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Benjamin P. Kleinstiver
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Miguel A. Moreno-Pelayo
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Lluis Montoliu
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Raul Perez-Jimenez
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

R.P.-J. conceived the project. R.P.-J., B.A.-L., B.P.K., A.S.-M., M.G., F.J.M.M., M.A.M.-P. and L.M. designed research and planned experiments. R.P.-J. performed phylogenetic analysis and ancestral sequence reconstruction. B.A.-L., Y.J. and S.S. cloned and expressed proteins and performed in vitro experiments. L.T.H. performed HT-PAMDA experiments. L.T.H., R.A.S. and B.P.K. analysed HT-PAMDA data. B.A.-L., Y.J,. S.S., M.M., A.F., Y.B., S.F.-P., L.S., A.S.-M., M.G., M.A.M.-P. and L.M. performed functional validation of anCas in mammalian cells, sequencing experiments and bioinformatic analysis. B.A.-L., Y.J., R.P.-J., J.A.G., A.R., A.D. and W.V. designed, analysed and represented structural data. All authors participated in discussions and provided ideas for the work. R.P.-J., F.J.M.M., M.A.M.-P. and L.M. wrote the original paper, and all authors revised and edited the manuscript.

Corresponding author

Correspondence to Raul Perez-Jimenez.

Ethics declarations

Competing interests

R.P.-J. and B.A.-L. are co-inventors on a patent application (European Patent Application EP21382474) filed by CIC nanoGUNE and licensed to Integra Therapeutics S.L. relating to work in this article. A.S.-M. and M.G. are cofounders of Integra Therapeutics S.L. B.P.K. is an inventor on patents and/or patent applications filed by Mass General Brigham that describe genome engineering technologies, including the HT-PAMDA method (WO2021151065). B.P.K. is a consultant for EcoR1 Capital and is an advisor to Acrigen Biosciences, Life Edit Therapeutics and Prime Medicine. The remaining authors declare no competing interests.

Peer review

Peer review information

Nature Microbiology thanks the anonymous reviewers for their contribution to the peer review of this work.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Extended data

Extended Data Fig. 1 Posterior probability distribution for each inferred residue of all ancestral anCas endonucleases.

The residue with the highest posterior probability is assigned at each position. The posterior average probability of each anCas is indicated in brackets. In all cases, posterior probability average is close to 1 except for FCA anCas which shows an average value of 0.74.

Extended Data Fig. 2 Alignment of the amino acid sequences from PAM interacting (PI) domain of anCas and SpCas9.

Percentage of identity of the different anCas sequences with respect to SpCas9.

Extended Data Fig. 3 List of important mutations and domain organization of anCas compared to SpCas9.

Mutations of the main residues involved in PAM recognition are marked in blue. These alterations suggest possible differences in PAM recognition abilities in FCA anCas and possibly in BCA anCas. Bottom figure depicts domain organization and structural alignment of SpCas9-FCA and SpCas9-PDCA anCas. Ancestral anCas are grey colored and SpCas9 colored by domains.

Extended Data Fig. 4 Structural predictions of anCas and SpCas9 by AlphaFold2.

Structures are colored by pLDDT score according to the color bar.

Extended Data Fig. 5 Activity of FCA anCas H838A endonuclease on a supercoiled DNA substrate.

(a) In vitro cleavage assay for anCas FCA H838A on a 4007 bp substrate at different reaction times showing nicked and linear fractions. (b) Quantification of total cleavage fraction at different reaction times and exponential fits (lines). (c) Quantification of fraction nicked at different times. (d) Quantification of DSB cleavage. Single-exponential fits were used to obtain kcleave and maximum fraction cleaved (amplitude). Values reported as mean, where n = 2.

Extended Data Fig. 6 PAM determination of anCas enzymes.

(a) Example of in vitro cleavage assay to obtain 278 bp fragment for NGS analysis. (b) Weblogo of the different PAM recognized by anCas and SpCas9. (c) Heatmaps illustrating the total reads for each of the possible 256 NNNN PAMs, analyzed from NGS of the 278 bp cleaved DNA fragments from panel a. (d) In vitro cleavage assay using the PAM sequence TCC.

Extended Data Fig. 7 HT-PAMDA determined PAM profiles of younger anCas enzymes.

PAM profiles of anCas enzymes and SpCas9 as determined by HT-PAMDA. Rate constants corresponding to Cas cleavage activity on each of the 256 NNNN PAMs are illustrated as mean log10 values of cleavage reactions against two unique spacer sequences. For comparison, the SpCas9 is re-plotted from Fig. 4.

Extended Data Fig. 8 Trans-activity of FCA anCas, BCA anCas and SpCas9 on M13 phage ssDNA.

Nonspecific M13 ssDNA cleavage with sgRNA and complementary (or not) 85nt ssDNA activator with no sequence homology to M13 circular ssDNA. FCA anCas can cleave the ssDNA substrate in the presence of the activator, whereas BCA anCAs and SpCas9 do not cleave the same substrate.

Extended Data Fig. 9 Analysis of the in vivo activity of anCas variants.

Alignments generated by Jalview program of the wild-type and the most frequent edited alleles (indels) detected by Mosaic Finder in (a) OCA2 and (b) TYR genes after NHEJ cell repair in HEK 293T cells. Heatmaps are shown underneath the alignments highlighting the frequencies of the top-7 most frequent alleles generated after cleavage and repair with SpCas9, PDCA, PCA, SCA and BCA anCas, once normalized with respect to the total number of indels for each Cas. The guide, the PAM and the DSB theoretical site are marked in the figure. For the mutation nomenclature of each allele, we consider the first nucleotide of the PAM as +1. Numbers within the allele sequences represent the length of insertions or deletion in the exact location indicated by the first figure. Example: -4Ins1, insertion of 1 nucleotide four bases upstream the PAM.

Extended Data Fig. 10 Traffic Light Reporter cleavage assay targeting gene TLR.

The relative NHEJ frequency is estimated by the number of RFP-positive cells and is normalized to SpCas9. Bars represent the average value of two independent experiments indicated by the black dots.

Supplementary information

Supplementary Information

Supplementary Figs. 1–5, Tables 1–16, Notes 1–4 and references.

Reporting Summary

Source data

Source Data Fig. 1

Amino acid sequences of ancestral anCas.

Source Data Fig. 4

HT-PAMDA data summary.

Source Data Fig. 5

Unprocessed gels.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alonso-Lerma, B., Jabalera, Y., Samperio, S. et al. Evolution of CRISPR-associated endonucleases as inferred from resurrected proteins. Nat Microbiol 8, 77–90 (2023). https://doi.org/10.1038/s41564-022-01265-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41564-022-01265-y

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing